F5

Coagulation factor V · P12259 · F5 on Sugi Atlas →

1,702 patent compounds predicted against F5, 1,455 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Razaxaban (SCHEMBL677372)	1.00	2/20
Edoxaban (SCHEMBL330046)	1.00	1/20
Edoxaban (SCHEMBL713017)	1.00	1/20
Edoxaban (SCHEMBL713195)	1.00	1/20
Edoxaban (SCHEMBL714523)	1.00	1/20
Edoxaban (SCHEMBL715418)	1.00	1/20
Edoxaban (SCHEMBL715737)	1.00	1/20
Edoxaban (SCHEMBL715818)	1.00	1/20
Edoxaban (SCHEMBL716662)	1.00	1/20
Edoxaban (SCHEMBL1312016)	1.00	1/20
Edoxaban (SCHEMBL1504007)	1.00	1/20
Edoxaban (SCHEMBL2125499)	1.00	1/20
Edoxaban (SCHEMBL330034)	0.99	1/20
Edoxaban (SCHEMBL2464257)	0.99	1/20
Edoxaban (SCHEMBL2569931)	0.92	1/20
Hydrochloric Acid (SCHEMBL3310330)	0.91	1/20
SCHEMBL1253442	0.89	1/20
SCHEMBL1252776	0.88	1/20
SCHEMBL1252835	0.88	1/20
Hydrochloric Acid (SCHEMBL2188304)	0.88	1/20

Clinical trials — most relevant to F5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）	PHASE4	RECRUITING
Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor	PHASE4	RECRUITING
Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal	PHASE4	COMPLETED
Levonorgestrel-releasing Intrauterine System in Patients With Endometriosis	PHASE4	COMPLETED
Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19	PHASE4	UNKNOWN
Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography	PHASE4	UNKNOWN
An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.	PHASE3	COMPLETED
Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor	PHASE3	UNKNOWN
Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A	PHASE3	COMPLETED
A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A	PHASE3	ACTIVE_NOT_RECRUITING
Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B	PHASE2	COMPLETED
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome	PHASE1	COMPLETED
Pharmacokinetics of rFVIIIFc at Two Vial Strengths	PHASE1	COMPLETED
A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People	PHASE1	COMPLETED
Safety and Dosing Evaluation of REG1 Anticoagulation System	PHASE1	COMPLETED
Risk Factors of Neonatal Thrombosis	nan	COMPLETED
Hypolipemic Treatment in Acute Coronary Syndrome (ACS): Antithrombotic Effects	nan	UNKNOWN
Correlation Between PT and INR to Factor 7	nan	UNKNOWN
Risk Factors of Venous Thromboembolism in Women During Hormonal Exposure	nan	RECRUITING
Coagulation After Intravenous Methylprednisolone Administration	nan	COMPLETED
Heparin Management During Cardiopulmonary Bypass in Children	nan	COMPLETED
Thrombophilic Risk Factors in Preterm and Infants Treated at Ha'Emek Medical Center Between the Years 1990 to 2010	nan	UNKNOWN
Pattern of Menorrhagic Female Attending the Hematology Unit in Assuit University Children Hospital	nan	NOT_YET_RECRUITING
Cross-sectional Study on Prevalence of Coagulation Factors Deficiency in Assiut University Children Hospital	nan	UNKNOWN
A Study That Collects Participant Data and Biospecimens to Analyze Pathogenic Exosomes That Mediate Increased Vascular Dementia Risk in Individuals With Herpes Zoster.	nan	RECRUITING
Analysis of the Coagulopathy Developed by COVID-19 Infected Patients	nan	COMPLETED
Comparative Outcomes of PCC and Recombinant Activated Factor VIIa in Trauma-Associated Massive Transfusion	nan	RECRUITING
Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer	nan	UNKNOWN
Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19	nan	NO_LONGER_AVAILABLE
Individualized Multimodal Hemostasis Evaluation Pyramid (IMHOTEP)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a F5 binder may also engage these)

Protein	Name	Similarity
Q28107	—	1.000	Q28107 →
Q9GLP1	—	1.000	Q9GLP1 →
Q06194	—	1.000	Q06194 →
P12263	—	0.998	P12263 →
O18806	—	0.997	O18806 →
F8	Coagulation factor VIII	0.997	landscape →
O88783	—	0.996	O88783 →
O88422	—	0.988	O88422 →
P34822	—	0.988	P34822 →
Q7Z7M9	—	0.987	Q7Z7M9 →
P35054	—	0.987	P35054 →
F8W3R9	—	0.986	F8W3R9 →
P26342	—	0.986	P26342 →
Q96PD2	—	0.986	Q96PD2 →
P47984	—	0.986	P47984 →
Q9R097	—	0.986	Q9R097 →
Q9Z0T6	—	0.985	Q9Z0T6 →
P52583	—	0.985	P52583 →
Q9ZVI7	—	0.985	Q9ZVI7 →
Q9BQ16	—	0.985	Q9BQ16 →
Q95JR7	—	0.984	Q95JR7 →
Q7SZN0	—	0.984	Q7SZN0 →
Q58L91	—	0.984	Q58L91 →
P42099	—	0.984	P42099 →
O95393	—	0.984	O95393 →
A2RUV9	—	0.984	A2RUV9 →
Q58L90	—	0.984	Q58L90 →
Q9D5K1	—	0.984	Q9D5K1 →
Q593B6	—	0.984	Q593B6 →
Q800B9	—	0.984	Q800B9 →